Literature DB >> 17722705

Desmin as a marker of proteinuria in early stages of membranous nephropathy in elderly patients.

M Maruyama1, H Sugiyama, K Sada, M Kobayashi, Y Maeshima, Y Yamasaki, H Makino.   

Abstract

AIMS AND
METHOD: Idiopathic membranous nephropathy (IMN) is the most common cause of nephrotic syndrome in adults worldwide. Many patients with IMN are elderly, but little is known about the relationship regarding the morphological stage determined by electron microscopy (EM), the amount of proteinuria, and the expression of glomerular podocyte markers such as desmin and nephrin in nephrotic glomeruli in IMN. We studied 59 patients with histopathologically proven IMN. We compared the clinical features, EM stage classification, and the immunohistochemical features of glomerular expression of podocyte markers, including desmin and nephrin, between older (age > or = 60 years) and younger (age < 60 years) patients. We also investigated these parameters in patients with minimal-change nephrotic syndrome (MCNS), minor glomerular abnormalities (MGA), and normal kidneys as age-matched controls.
RESULTS: Prevalence of nephrotic syndrome was significantly higher in the older (52.9%) than the younger group (20.0%) of IMN. The level of proteinuria was higher in early stages (Stages I + II) than in late stages (Stages III + IV) in IMN. The glomerular expression of desmin in podocytes was significantly higher in IMN as compared to MCNS, MGA, or age-matched controls. Desmin expression was significantly increased in earlier EM stages (Stages I + II) and in higher proteinuric group (daily proteinuria > or = 1 g) of older patients with IMN. Reciprocally, the reduced expression of nephrin was associated with the early EM stages (Stages I + II) of patients with IMN.
CONCLUSIONS: We conclude that the expression of desmin in podocytes is upregulated in patients with IMN as compared to other glomerular diseases including MCNS or MGA, or to controls. In elderly patients with IMN, desmin expression was associated with early EM stages and heavy proteinuria, which may reflect phenotypic alteration of the podocyte.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17722705     DOI: 10.5414/cnp68073

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

1.  Unique microstructures and podocytic infolding in glomerular basement membrane associated with collagen diseases: a report of three cases.

Authors:  Hitoshi Sugiyama; Mie Maruyama; Hiroshi Morinaga; Tatsuyuki Inoue; Kei-Ichi Takiue; Yoko Kikumoto; Masaru Kinomura; Ken-Ei Sada; Shigeru Akagi; Shinji Kitamura; Yohei Maeshima; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2008-10-08       Impact factor: 2.801

2.  The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age.

Authors:  Mariya T Sweetwyne; Jeffrey W Pippin; Diana G Eng; Kelly L Hudkins; Ying Ann Chiao; Matthew D Campbell; David J Marcinek; Charles E Alpers; Hazel H Szeto; Peter S Rabinovitch; Stuart J Shankland
Journal:  Kidney Int       Date:  2017-01-04       Impact factor: 10.612

3.  The expression of cytoskeletal proteins in kidney specimens of children with primary focal segmental glomerulosclerosis.

Authors:  A Gheissari; D Taheri; S Mozafarpour; H Beigy; P Samanianpoor; A Merrikhi; Z Farajzadegan
Journal:  Indian J Nephrol       Date:  2012-11

4.  Minimal change disease of the kidney in a young Sprague Dawley rat.

Authors:  Kyohei Yasuno; Kumi Honda; Shinobu Hakamata; Kiyonori Kai; Kazuhiko Mori
Journal:  J Toxicol Pathol       Date:  2017-11-25       Impact factor: 1.628

5.  Podocyte autophagy is associated with foot process effacement and proteinuria in patients with minimal change nephrotic syndrome.

Authors:  Ayu Ogawa-Akiyama; Hitoshi Sugiyama; Masashi Kitagawa; Keiko Tanaka; Yuzuki Kano; Koki Mise; Nozomu Otaka; Katsuyuki Tanabe; Hiroshi Morinaga; Masaru Kinomura; Haruhito A Uchida; Jun Wada
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.